Alerta

ANTI-IL23 AND ANTI-TNFa ANTIBODIES: COMPOSITIONS AND VETERINARY USE

Resumen de: US20260209333A1

0000 Provided are various embodiments relating to caninized, felinized, or equinized antibodies that bind canine, feline, and/or equine IL23 and/or TNFα, including bispecific antibodies that bind to both IL23 and TNFα. Such antibodies can be used alone or in combination in methods to treat canine, feline, and/or equine subjects with inflammatory conditions, such as inflammatory conditions in canines and felines, such as inflammatory bowel disease (IBD), osteoarthritis, and gastroenteritis.

METHODS, KITS AND COMPOSITIONS FOR THE TREATMENT OF FOOD PROTEIN INDUCED ENTEROCOLITIS SYNDROME AND IRRITABLE BOWEL SYNDROME

Resumen de: US20260209366A1

This invention describes methods, kits, and compositions for treating Food Protein-Induced Enterocolitis Syndrome (FPIES) and a food-triggered endotype of IBS by modulating the IL-4/IL-13→IL-4Rα axis and/or the OX40-OX40L costimulatory pathway, with patient selection and monitoring guided by blood biomarkers (elevated OX40L on dendritic cells and/or OX40 on lymphocytes, including food antigen-stimulated assays). In case examples, IL-4Rα blockade (e.g., dupilumab) produced rapid, durable clinical remission with successful food reintroduction, accompanied by reduced dendritic-cell OX40L and modulation of circulating CRTH2+ Tc2 cells, whereas OX40L-low, non-food-trigger IBS showed no response—supporting a biomarker-defined responder population. Collectively, this invention demonstrates a precision framework in which IL-4Rα and OX40/OX40L antagonists—alone or in combination—enable diet liberalization and induce tolerance in FPIES and food-triggered IBS.

METHOD FOR EXAMINING INFLAMMATORY BOWEL DISEASE AND METHOD FOR SCREENING THERAPEUTIC AGENT

Resumen de: WO2026155051A1

The present invention provides an examination method for identifying a biomarker capable of detecting the remission phase of an inflammatory bowel disease, and assisting in the diagnosis of the inflammatory bowel disease, the monitoring of disease progression, or the determination of therapeutic effect.　Focusing attention on myeloid immune cells that play an important role in the pathogenesis of inflammatory bowel disease, the present inventors considered that young myeloid immune cells potentially increase even in the remission phase and may induce transition to the active phase by progression of the disease. The present inventors then proceeded with intensive studies thereon. As a result, the present inventors found that CD11b, CD33, and CD84-positive (CD11b+CD33+CD84+) cells, which are precursor cells of myeloid immune cells, can serve as blood markers for inflammatory bowel disease. Further investigation revealed that Membrane-Spanning 4-Domains A3 (Ms4a3)-positive (Ms4a3+) cells, and Ms4a3 and CD84-positive (Ms4a3+CD84+) cells significantly increase not only in the active phase but also in the remission phase, and are significantly greater in number in the active phase than in the remission phase.

AUTOMATIZED DETECTION OF INTESTINAL INFLAMMATION IN CROHN'S DISEASE USING CONVOLUTIONAL NEURAL NETWORK

Resumen de: US20260212495A1

0000 The invention relates to system and methods for predicting and/or diagnosing of IBD from ultrasound images according to one or more of diagnostic signs.

METHOD TO PREDICT SENSITIVITY TO EMULSIFIER

Resumen de: WO2026150017A1

The present invention relates to a method to predict the sensitivity of a subject to emulsifiers. Here, the inventors explored the use of an in vitro microbiota system and metagenome-based bioinformatic modeling to predict CMC sensitivity of a given microbiota. They found that CMC sensitivity associated with a unique metagenomic signature, supporting the notion that emulsifier sensitivity could be predicted from metagenomic data. They next confirmed that microbiotas predicted to be CMC-sensitive conferred CMC sensitivity when transplanted into colitis-prone IL-10-/- germfree mice. This approach validated the ability of an ex vivo approaches to predict CMC-sensitivity, thereby advancing development of microbiota- based personalized nutrition strategies. Thus, the present invention relates to a method to predict the sensitivity of a subject to emulsifiers comprising determining in a sample obtained from the subject the relative abundance of the microbiota-derived DNA markers listed in the Table A.

CIRCULATING PERIPHERAL BLOOD MONOCYTES AS A PROGNOSTIC MARKER FOR COMPLICATED AND RESISTANT CROHN'S DISEASE

Resumen de: US20260201470A1

0000 Described herein are systems and methods for identifying gene clusters in patients that have Crohn's Disease (CD). Further provided herein are systems and methods for determining or characterizing a Crohn's Disease (CD) subtype status in a subject having CD, selecting a treatment for a subject, or treating a subject.

COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE

Resumen de: EP4775989A2

The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring RORγt⁺Th or RORγt⁺Treg cell levels and treating the subject accordingly.

MEASUREMENT OF HYDROGEN SULFIDE DURING BREATH TESTING

Resumen de: WO2018156937A1

Described herein are methods of detecting levels hydrogen sulfide (H2S) to diagnose H2S positive disease or conditions. Examples of H2S positive diseases and conditions include small intestinal bacterial overgrowth, diarrhea, fatigue, bowel urgency and abdominal pain. The H2S level can guide treatments for subjects who have high levels of H2S.

METHODS AND MODELS FOR POST-OPERATIVE RECURRENCE IN CROHN'S DISEASE

Resumen de: US20260193710A1

Provided herein are methods, systems, compositions and kits for modeling post-operative recurrence (POR) or postoperative prophylaxis persistence (POPP) in Crohn's disease patients. The present disclosure provides clinical, serologic, and genetic factors predictive of POR in patients with Crohn's disease. Also provided are clinical, serologic, and genetic factors predictive of POPP in Crohn's disease patients. The clinical, serologic, and genetic factors of the present disclosure are useful for selecting for prognosing, diagnosing, treatment, treating, monitoring a treatment, or optimizing a treatment for a Crohn's disease patient.

PHARMACEUTICAL COMPOSITION FOR TREATING ULCERATIVE COLITIS AND PREPARATION THEREOF

Resumen de: US20260191892A1

0000 The present invention provides a pharmaceutical composition including berberine, militarine, liquiritin, curcumin and atractylenolide III. The pharmaceutical composition is proven to be effective on ulcerative colitis modulating targets including MAOA, MAPK14, AHR, PTGS2, PLA2G1B, and ALOX5. The present invention further provides a method of preparing the pharmaceutical composition including optimization of extraction, determining the quality markers, and optimization of temperature. The present invention further provides a method of treating or alleviating ulcerative colitis.

USEFUL COMPOUNDS FOR MODULATING INFLAMMATION

Resumen de: US20260193242A1

0000 The present disclosure provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R to R<3 >and X are defined herein; pharmaceutical compositions; dosage forms comprising the compounds or pharmaceutical compositions, and methods of treating inflammation, decreasing inflammation, decreasing an inflammatory marker, treating inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, or treating sepsis in a subject in need thereof, comprising administering the compounds, pharmaceutical compositions or dosage forms disclosed herein to a subject in need thereof. 0000

Diagnosis and treatment path recommendation method based on IBS multi-dimensional data

Resumen de: CN122337553A

The invention discloses a diagnosis and treatment path recommendation method based on IBS multi-dimensional data, and relates to the technical field of intelligent diagnosis and treatment, and the method comprises the following steps: S1, constructing an IBS treatment scheme library which comprises standardized treatment schemes corresponding to different diagnosis types and different disease severity degrees of IBS, the standardized treatment schemes at least comprise review suggestions, drug recommendation, probiotic recommendation and nursing guidance, and each treatment scheme is associated with a corresponding IBS multi-dimensional data feature threshold. According to the diagnosis and treatment path recommendation method based on the IBS multi-dimensional data, the limitation of single diagnosis data dimension in the prior art is broken through, four core dimensions of symptom data, physical sign data, laboratory examination data and medical history data of a patient are comprehensively integrated, and the symptom data is ensured to be free of omission by combining dual modes of patient autonomous filling and reporting and doctor inquiry; objectivity of physical sign data is guaranteed through professional medical equipment, laboratory inspection data are synchronously obtained from a hospital inspection system, and errors are reduced.

Inflammatory bowel disease assessment method and system

Resumen de: CN122337628A

The invention belongs to the technical field of medical diagnosis assistance, and provides an inflammatory bowel disease assessment method and system.The method includes the steps that biological sample data of a target object is obtained and preprocessed to standardize index data, and the index data is obtained; and calculating multiple scores representing the individual state of the target object based on the preprocessed biological sample data, and constructing a comprehensive evaluation index for quantitatively evaluating the inflammatory bowel disease of the target object based on the scores. According to the scheme provided by the invention, a multi-dimensional comprehensive evaluation index is constructed by integrating multiple index data, so that the pathophysiological essence of the inflammatory bowel disease can be comprehensively and accurately reflected, misdiagnosis or missed diagnosis caused by single-dimensional evaluation is effectively avoided, and the diagnosis accuracy is improved. And a non-invasive, convenient and standardized technical solution is provided for diagnosis, illness monitoring and curative effect evaluation of the inflammatory bowel disease.

Method for analyzing relationship between intestinal microbiota and emotional symptoms of IBS patient

Resumen de: CN122326775A

The invention relates to a method for analyzing a relationship between intestinal microbiota and an emotional symptom of an IBS patient. The method comprises the following steps: determining a causal relationship between the intestinal microbiota and the emotional symptom of the IBS patient; determining that the emotional symptom is caused by reduction of abundance of A. shahii in the intestinal microbiota; determining that the emotional symptom is caused by the reduction of indole produced by metabolism of the intestinal microbiota, and the reduction of indole is caused by the reduction of abundance of A. shahii; determining that the emotional symptom is caused by the decrease of TnAse generated by the intestinal microbiota, the decrease of TnAse is caused by the decrease of abundance of A. shahii, and the decrease of indole is caused by the decrease of TnAse; determining that the emotional symptom is caused by the weakening of AhR signal transduction in the vDG of the IBS patient, and the weakening of AhR signal transduction is caused by the reduction of indole; and determining that the emotional symptoms are caused by the weakening of vDG granular cell viability and the weakening of the vDG granular cell viability is caused by the weakening of AhR signal transduction, thereby obtaining an analysis result that the intestinal microbiota regulates and controls the emotional symptoms through the A. shahii-TnAse-indole-AhR-vDG signal pathway.

Clinical prediction model of anal fistula occurrence probability of Crohn disease patient and design method

Resumen de: CN122337675A

The invention provides a clinical prediction model of anal fistula occurrence probability of a Crohn disease patient and a design method, and belongs to the technical field of clinical medicine. The risk prediction model comprises: an input module receiving patient parameter indexes composed of age during diagnosis, biological agent mode switching and Monte's performance typing during primary definite diagnosis; the processing module is connected with the input module and is used for calculating the evaluation and prediction probability of the anal fistula of the patient suffering from the Crohn disease according to the following formula on the basis of the age during diagnosis, the biological agent mode switching and the Monte performance typing data during primary definite diagnosis; the output module is connected with the processing module and outputs the anal fistula risk probability, obtained by the risk prediction model, of the patient suffering from the Rohn disease. And respectively verifying the prediction model in the training set and the verification set by adopting the area under the curve of the working characteristic curve of the subject and the calibration curve so as to judge the distinction degree and the calibration degree of the prediction model. The risk of anal fistula of a patient suffering from Crohn's disease can be accurately predicted before treatment.

Method of Diagnosing and Treatment of Crohn's Disease and Ulcerative Colitis

Resumen de: US20260185998A1

Methods of diagnosing Crohn's disease and ulcerative colitis in subjects is provided based on the determination of metabolites in urine samples, such as serine, hypoxanthine, kynurenine, threonine, indoxylsulfate, phenylacetylglutamine, 5-hydroxy-6-indolyl-O-sulfate, 5-(δ-carboxybutyl) homocysteine, sialic acid, guanidinosuccinic acid (GSA), glutamyl(iso) leucine, trigonelline, cresol sulfate, an anion having m/z: RMT: polarity of 345.1553:0.770: n, aminohippurate: GSA ratiometric biomarker, unknown anion (160.0615:0.830: n): tyrosine ratiometric biomarker and GSA×Tyr: AHA×(an anion having m/z: RMT: polarity of 160.0615:0.830: n) ratiometric biomarker.

Application of NUCB1 in prevention and/or treatment of autoimmune diseases

Resumen de: CN122297639A

The invention provides an application of NUCB1 in preventing and/or treating autoimmune diseases, and particularly provides an application of an NUCB1 gene, or a protein thereof or an accelerant thereof in preparing a composition or a preparation, and the composition or the preparation is used for preventing and/or treating the autoimmune diseases. The NUCB1 gene, or the protein thereof, or the promoter thereof can significantly prevent and/or treat autoimmune diseases, especially can effectively treat systemic lupus erythematosus, atopic dermatitis, rheumatoid arthritis, psoriasis, multiple sclerosis or Crohn's disease.

Label-free cell screening model of GPR183 receptor and application of label-free cell screening model in preparation of drugs

Resumen de: CN122278770A

The invention relates to a method for screening drugs for diseases closely related to unmarked G-protein coupled receptors (GPCR), in particular to an unmarked cell screening model of a GPR183 receptor and application of the unmarked cell screening model in preparation of drugs. And the unmarked cell screening model is a stably transfected cell strain CHO-K1-GPR183 with high expression of a GPR183 receptor. The GPR183 receptor stimulant compound N-demethylated nuciferine is obtained by screening through the GPR183 cell screening model established in the invention. At present, researches show that the GPR183 receptor is closely related to the occurrence and development of neuroinflammation/autoimmune diseases such as multiple sclerosis, colitis, type I diabetes and arthritis, cancers and metabolic diseases, so that a seedling compound can be provided for the development of medicines for related diseases.

GENETIC PREDICTOR FOR IL18 DRIVEN DISEASE

Resumen de: WO2026136763A1

Provided are methods of generating a polygenic score (PGS) to identify or predict interleukin- 18 (IL- 18) driven disease in a subject, along with methods of treating subjects with various diseases and conditions, such as inflammatory bowel disease, determined to have IL- 18 driven disease or inflammasome-mediated disease based on a PGS.

PROSTATE-SPECIFIC MEMBRANE ANTIGEN AS AN IMAGING BIOMARKER IN INFLAMMATORY BOWEL DISEASE

Resumen de: WO2025038942A1

Disclosed are methods for imaging inflammation associated with inflammatory bowel disease (IBD), including administering to a subject a prostate-specific membrane antigen (PSMA)-targeted imaging agent and taking an image.

Application of TLR8 in preparation of products for diagnosing and treating ulcerative colitis

Resumen de: CN122259877A

The invention discloses application of TLR8 in preparation of a product for diagnosing and treating ulcerative colitis, and belongs to the technical field of biological medicines. The invention provides an application of TLR8 in preparation of an ulcerative colitis diagnostic product, the diagnostic product is used for detecting the expression level of TLR8 in a peripheral blood sample, and the diagnostic product comprises a detection reagent, a detection kit and a detection chip; meanwhile, the invention provides application of TLR8 in preparation and/or screening of drugs for treating ulcerative colitis and application of a TLR8 inhibitor in preparation of drugs for treating or relieving ulcerative colitis. The medicine can be used for reducing the phosphorylation level of p65 in an NF-kappa B pathway by inhibiting the expression of TLR8, so that the intestinal inflammatory response is relieved. The invention clarifies the association between TLR8 and ulcerative colitis, provides a new target and detection means for the early diagnosis of ulcerative colitis, provides a new idea and drug research and development direction for the treatment of the disease, and has important clinical application value and industrialization prospect.

Diagnostic model of inflammatory bowel disease subtype and construction method thereof

Resumen de: CN122245701A

The invention provides an inflammatory bowel disease subtype diagnosis model and a construction method thereof, and the diagnosis model is characterized in that an RNA editing characteristic spectrum capable of specifically distinguishing Crohn's disease and ulcerative colitis is extracted from a PBMC sample obtained by minimally invasive acquisition through a set of innovative bioinformatics flow, and the RNA editing characteristic spectrum is used for constructing the inflammatory bowel disease subtype diagnosis model. And a machine learning model is constructed and trained by using the characteristic spectrum, and finally accurate and automatic diagnosis of the IBD subtype is realized.

Preparation method and application of oyster oligopeptide for relieving DSS-induced ulcerative colitis

Resumen de: CN122229982A

The invention belongs to the technical field of marine product function application, functional food and biology, and discloses oyster oligopeptide for relieving dextran sodium sulfate (DSS) induced ulcerative colitis and a preparation method and application thereof. A DSS induced human normal colonic epithelial cell injury model is taken as a guide, oyster meat is subjected to enzymolysis, degreasing and alcohol precipitation preparation and purification to obtain oyster zymolyte, two oyster peptides are obtained through identification, bioinformatics screening and synthesis verification, and the amino acid sequences are shown as SEQ ID NO.1-2. The oyster oligopeptide has relatively strong antioxidant and anti-inflammatory activity, can effectively relieve DSS-induced NCM460 cell injury, has an effect superior to that of a positive control 5-aminosalicylic acid, and can be used for preparing medicines for relieving ulcerative colitis and foods and health-care products for adjuvant therapy of ulcerative colitis.

COMPANION DIAGNOSTIC METHODS OF ADMINISTERING PDE4 INHIBITORS

Resumen de: WO2026128869A1

Personalized methods of determining a reference PDE4 Inhibitor Resistance Metric for treating a future patient in need of treatment, and methods of treating a subject with an inflammatory bowel disease are provided.

Combined marker for detecting Crohn disease and application thereof

Nº publicación: CN122218255A 16/06/2026

Solicitante:

THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
\u4E2D\u5C71\u5927\u5B66\u9644\u5C5E\u7B2C\u4E00\u533B\u9662

Resumen de: CN122218255A

The invention discloses a combined marker for detecting Crohn's disease and application of the combined marker, and relates to the technical field of biology and medicine. The combined marker is prepared from the following components: chenodeoxycholic acid, lithocholic acid, ursodeoxycholic acid, glycochenodeoxycholic acid, glycolithocholic acid, glycoursodeoxycholic acid, taurochenodeoxycholic acid, taurocholic acid, taurocholic acid, tauroursodeoxycholic acid, cholic acid, glycocholic acid, taurocholic acid, glycodeoxycholic acid and taurodeoxycholic acid. Adding glycylcholic acid sulfate and isolithocholic acid; the combined marker can be used for clinical diagnosis or monitoring of Crohn's disease. The metabonomics combined marker for Crohn disease diagnosis is explored, a diagnosis and identification method which is simple and convenient to detect, low in cost and easy to accept by patients is created, a traditional diagnosis mode can be well replaced, and the metabonomics combined marker has great significance in clinical diagnosis and treatment of Crohn diseases and has popularization value.